Phase II trial of VM-26 in patients with metastatic malignant melanoma. 1978

R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011034 Podophyllotoxin A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. Epipodophyllotoxin,CPH86,Condyline,Condylox,Podocon-25,Podofilm,Podofilox,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-Isomer,Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-Isomer,Wartec,Warticon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
January 1994, Investigational new drugs,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
January 1987, Cancer immunology, immunotherapy : CII,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
January 1985, Cancer treatment reports,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
October 1983, American journal of clinical oncology,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
April 1988, Investigational new drugs,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
August 1986, Cancer treatment reports,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
January 1982, Cancer treatment reports,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
June 1982, Cancer treatment reports,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
December 2004, Melanoma research,
R E Bellet, and R B Catalno, and M J Mastrangelo, and D Berd, and L S Koons
January 1981, Cancer treatment reports,
Copied contents to your clipboard!